Xenetic Biosciences Inc (XBIO) FinancialsXBIOFinancialXenetic Biosciences Inc

Evaluating the bottom line, Xenetic Biosciences Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -147.09%, while the net margin is -140.73%. These profitability ratios, combined with a Return on Equity (ROE) of -47.05%, provide a clear picture of how effectively XBIO converts its operational activities into shareholder value.

In the context of the broader market, XBIO competes directly with industry leaders such as MGRX and SNGX. With a market capitalization of $7.69M, it holds a significant position in the sector. When comparing efficiency, XBIO's gross margin of N/A stands against MGRX's -342.77% and SNGX's N/A. Such benchmarking helps identify whether Xenetic Biosciences Inc is trading at a premium or discount relative to its financial performance.

Xenetic Biosciences has shown a significant reduction in net losses, with a Q1 2026 net loss of approximately $0.5 million, down 49% from the previous year. The company has also seen a 36% increase in royalty revenue, reflecting positive developments in its strategic partnerships.